secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-01-27T23:59:59+00:00
Accession:  0001437749-25-001886
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia's CardiAMP HF Phase 3 trial accepted for late-breaking presentation at ACC 2025
--------------------------------------------------------------------------------

- Results of double-blind, randomized, placebo-controlled CardiAMP HF Phase 3 study accepted for late-breaking symposium at ACC 2025 in Chicago, March 29-31.
- Presentation by Dr. Amish N. Raval on March 30, 2025, in Featured Clinical Research II session.
- CardiAMP HF trial evaluates autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF).
- Late-breaking clinical trial session highlights key upcoming results at a leading cardiovascular conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925001886/0001437749-25-001886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925001886/bcda20250124_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-001886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer